 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
Trial completion date, Trial initiation date, Trial primary completion date: A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine (clinicaltrials.gov) - Dec 15, 2023
P1, N=8, Not yet recruiting, Sponsor: Kinnov Therapeutics
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
New P1 trial: A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine (clinicaltrials.gov) - Nov 27, 2023
P1, N=8, Not yet recruiting, Sponsor: Kinnov Therapeutics
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
Trial completion, Adverse events: COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - Mar 15, 2022
P2, N=154, Completed, Sponsor: Kinnov Therapeutics
Active, not recruiting --> Completed
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
Enrollment closed, Adverse events: COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - Sep 12, 2021
P2, N=154, Active, not recruiting, Sponsor: Kinnov Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
Trial completion date, Trial primary completion date, Adverse events: COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - Mar 2, 2021
P2, N=180, Recruiting, Sponsor: Kinnov Therapeutics
Recruiting --> Active, not recruiting Trial completion date: May 2021 --> Jan 2022 | Trial primary completion date: Feb 2021 --> Oct 2021
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
Enrollment open, Adverse events: COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - Mar 13, 2020
P2, N=180, Recruiting, Sponsor: Kinnov Therapeutics
Trial completion date: May 2021 --> Jan 2022 | Trial primary completion date: Feb 2021 --> Oct 2021 Not yet recruiting --> Recruiting
- | cyproheptadine/prazosin (KT-110) / Kinnov Therap
New P2 trial, Adverse events: COCKTAIL: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (clinicaltrials.gov) - Sep 26, 2019
P2, N=180, Not yet recruiting, Sponsor: Kinnov Therapeutics